Study guide
10.2 Suspect & Illegitimate Product Verification, Quarantine & Notification
NABP MPJE Multistate Pharmacy Jurisprudence Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pharmacist Licensure & Reciprocity
1.1 Initial Licensure Requirements & Examinations 1.2 License Renewal, Continuing Education (CE) & Status 1.3 Reciprocity, License Transfer & Multistate Licensure 1.4 Disciplinary Actions, Board Hearings, Sanctions & Reinstatement
2 Chapter 2: Pharmacy Personnel Roles & Supervision Ratios
2.1 Pharmacy Interns: Scope of Practice, Supervision & Preceptor Rules 2.2 Pharmacy Technicians: Registration, Certification & Permitted Duties 2.3 Technician-to-Pharmacist Ratios & Delegated Tasks 2.4 Non-Pharmacist Personnel & Automated Dispensing Technology Roles
3 Chapter 3: Prescriptive Authority & Practitioner Categories
3.1 Physicians, Dentists, Veterinarians & Podiatrists: Prescribing Scope 3.2 Mid-Level Practitioners: APNs, PAs, Optometrists & Independent Authority 3.3 Out-of-State, Foreign & Deceased Practitioner Prescriptions 3.4 Self-Prescribing & Prescribing for Family Members
4 Chapter 4: Patient Counseling & Drug Utilization Review (OBRA '90)
4.1 OBRA '90 Mandates & Prospective Drug Utilization Review (DUR) 4.2 Patient Counseling Requirements, Offer-to-Counsel & Documentation 4.3 Patient Profile Requirements & Retrospective DUR
5 Chapter 5: Advanced Pharmacist Practice & Collaborative Agreements
5.1 Collaborative Practice Agreements (CPAs) & Protocol-Based Care 5.2 Pharmacist Immunization Authority & Vaccine Administration Protocols 5.3 Medication Therapy Management (MTM) & Point-of-Care Testing (POCT) 5.4 Hormonal Contraceptive, Naloxone & Post-Exposure Prophylaxis (PEP/PrEP) Prescribing
6 Chapter 6: Federal Controlled Substances Act (CSA) & Scheduling
6.1 Controlled Substance Schedules (CI through CV) & Classification Criteria 6.2 DEA Registration: Types, Forms (224, 225, 363) & Renewal Cycles 6.3 Scheduled Listed Chemical Products (SLCPs) & Combat Methamphetamine Epidemic Act (CMEA)
7 Chapter 7: Controlled Substance Prescriptions & Legitimate Purpose
7.1 Corresponding Responsibility & Red Flags for Improper Prescribing 7.2 Required Components of Controlled Substance Prescriptions 7.3 Electronic Prescriptions for Controlled Substances (EPCS) & Security Requirements 7.4 Emergency Schedule II Prescriptions & Partial Filling Rules (CARA Act)
8 Chapter 8: Controlled Substance Ordering, Inventory & Recordkeeping
8.1 Ordering Schedule II Substances: CSOS & DEA Form 222 Execution 8.2 Controlled Substance Inventory Requirements (Initial, Biennial, Count Exactness) 8.3 Theft, Significant Loss (DEA Form 106) & Disposal/Destruction (DEA Form 41) 8.4 Prescription Transfers & Prescription Drug Monitoring Programs (PDMPs)
9 Chapter 9: Federal Pure Food, Drug & Cosmetic Act (FD&C Act) & Drug Safety
9.1 Adulteration vs. Misbranding: Statutory Definitions & Legal Violations 9.2 Prescription Labeling Requirements, Expiration Dates & Side Effect Statements 9.3 Poison Prevention Packaging Act (PPPA) & Child-Resistant Container Exemptions 9.4 Drug Recalls (Class I, II, III) & Market Withdrawals 9.5 Drug Product Selection, Generic Substitution & DAW Codes 9.6 Returning & Reusing Dispensed Drugs: Restocking, Redispensing & Repository Programs
10 Chapter 10: Drug Supply Chain Security Act (DSCSA) & Commercial Distribution
10.1 DSCSA Track-and-Trace Requirements: Transaction Information & Statements 10.2 Suspect & Illegitimate Product Verification, Quarantine & Notification 10.3 Prescription Drug Marketing Act (PDMA): Samples, Reimportation & Wholesale Distribution
11 Chapter 11: Compounding Standards: USP <795>, <797> & <800>
11.1 Section 503A vs. 503B Compounding Facilities (DQSA Architecture) 11.2 Non-Sterile Compounding (USP <795>) & Beyond-Use Dating (BUD) 11.3 Sterile Compounding (USP <797>): Air Quality, Cleanrooms & BUD 11.4 Hazardous Drug Handling (USP <800>): Engineering Controls & Personal Protective Equipment
12 Chapter 12: Pharmacy Operational Security, Records & Telepharmacy
12.1 Physical Pharmacy Security, Alarm Systems & Keyholder Rules 12.2 Mandatory Pharmacy Records Retention & Audit Inspection Readiness 12.3 Central Fill, Automated Dispensing Systems (ADS) & Telepharmacy Operations 12.4 HIPAA Privacy Rule, Patient Records & Breach Notification Protocols
10.2 Suspect & Illegitimate Product Verification, Quarantine & Notification
Key Takeaways Explain This Topic AI
A 'suspect product' is defined as a drug for which there is a 'reason to believe' it is counterfeit, stolen, adulterated, or unfit for distribution.
An 'illegitimate product' is defined as a drug for which there is 'credible evidence' confirming it is counterfeit, stolen, adulterated, or unfit for distribution.
Upon identifying suspect product, pharmacies must immediately execute physical and logical quarantine and investigate by verifying at least 3 packages or 10% of the lot.
Form FDA 3911 must be submitted to the FDA and immediate trading partners within 24 hours of determining a product is illegitimate.
All records related to suspect/illegitimate product investigations, Form FDA 3911 submissions, and dispositions must be retained for six (6) years.
Last updated: November 2026
10.2 Suspect & Illegitimate Product Verification, Quarantine & Notification
MPJE Core Concept: The DSCSA mandates that all authorized trading partners establish systems to detect, quarantine, investigate, and report suspect and illegitimate prescription drug products. A key exam distinction lies in the legal definition separating suspect product ( reason to believe ) from illegitimate product ( credible evidence ), as well as the strict 24-hour notification mandate using Form FDA 3911.
Defining Suspect vs. Illegitimate Products
The DSCSA establishes precise statutory definitions for products that pose potential or confirmed threats to public safety. Pharmacists must recognize the evidence threshold distinguishing suspect from illegitimate drugs.
1. Suspect Product Definition
A suspect product is a prescription drug for which there is a reason to believe that the product:
Is counterfeit , diverted, or stolen;
Is intentionally adulterated such that the product would result in serious adverse health consequences or death;
Is subject to a fraudulent transaction ; or
Is otherwise unfit for distribution such that the product would result in serious adverse health consequences or death.
Key Phrase for MPJE: "Reason to Believe" = Suspect Product .
2. Illegitimate Product Definition
An illegitimate product is a prescription drug for which there is credible evidence demonstrating that the product:
Is counterfeit , diverted, or stolen;
Is intentionally adulterated such that the product would result in serious adverse health consequences or death;
Is subject to a fraudulent transaction ; or
Is otherwise unfit for distribution such that the product would result in serious adverse health consequences or death.
Key Phrase for MPJE: "Credible Evidence" = Illegitimate Product .
Comparison Table: Suspect vs. Illegitimate Product
Statutory Attribute Suspect Product Illegitimate Product
Evidence Threshold Reason to Believe (e.g., suspicious packaging, damaged seal, unknown vendor) Credible Evidence (e.g., chemical analysis confirms fake API, confirmed stolen lot)
Primary Immediate Action Immediate physical & logical Quarantine + Investigation Immediate physical & logical Quarantine + FDA/Trading Partner Notification
FDA Reporting Required? Only if investigation confirms it is illegitimate (or cleared) YES — Mandatory Form FDA 3911 within 24 hours
Trading Partner Notice Not mandatory during initial suspect phase unless confirmed YES — Mandatory notification to immediate trading partners within 24 hours
Final Disposition Released to saleable inventory if cleared; destroyed if illegitimate Quarantine and ultimate destruction/disposition (never returns to trade)
The Four-Step Quarantine & Investigation Protocol
When a pharmacy or pharmacist identifies a suspect product in inventory or receives notification from the FDA or a manufacturer regarding a suspect lot, the pharmacy must immediately execute a mandatory four-step protocol: +-----------------------------------------------------------------------------+
- | SUSPECT PRODUCT INVESTIGATION FLOW |
- | |
- | [STEP 1: QUARANTINE] --> Isolate product physically & logically |
- | | |
- | [STEP 2: INVESTIGATE] --> Sample & verify 3 packages or 10% of lot |
- | | |
- | +---------+---------+ |
- | | | |
- | v v |
- | [CLEARED] [ILLEGITIMATE] |
- | Return to Notify FDA & Trading Partners via Form FDA 3911 |
- | inventory within 24 HOURS; dispose safely |
- +-----------------------------------------------------------------------------+
- Step 1: Immediate Quarantine
Physically separate the suspect product from active saleable inventory.
Store the product in a designated, secure quarantine area (e.g., locked cabinet or isolated room marked "QUARANTINED - DO NOT DISPENSE").
Logically lock the product in the pharmacy management software system to prevent processing or dispensing.
Step 2: Investigation & Verification
Validate the product identifier (NDC, Serial Number, Lot Number, Expiration Date) against trading partner records.
Perform package verification on at least 3 packages or 10% of the lot (whichever is greater), or all packages if fewer than 3.
Validate any transaction information and transaction history in the pharmacy's possession, and contact the manufacturer and wholesale distributor to verify lot numbers.
Inspect physical features for signs of tampering, altered labels, misspellings, uncharacteristic color/shape, or missing security seals.
Step 3: Resolution & Determination
The investigation must yield one of two outcomes:
Cleared (Determined Legitimate):
If the investigation reveals the product is authentic and legally acquired, the pharmacy may terminate the quarantine.
Document the investigation findings, rationale, and date of clearance.
Return the product to active saleable inventory.
Retain all investigation records for 6 years .
Confirmed Illegitimate:
Re-affirm quarantine status.
Proceed immediately to mandatory Step 4 (Notification and Disposition).
Form FDA 3911 & 24-Hour Notification Mandate
Upon making a determination that a product in possession is illegitimate (or upon receiving notification from FDA/trading partner that a product is illegitimate), the pharmacy must notify the FDA and all immediate trading partners within 24 hours .
Notification Mechanisms and Recipients
FDA Notification: Submit Form FDA 3911 electronically via the FDA’s online portal (FDA Drug Supply Chain Security Act Portal).
Immediate Trading Partners: Notify all trading partners to whom the pharmacy sold, transferred, or distributed the illegitimate product (or from whom it was received) within 24 hours. +-----------------------------------------------------------------------------+
- | FORM FDA 3911 MANDATORY TIMELINES |
- | |
- | * Initial Illegitimate Product Notification: Within 24 HOURS |
- | * Cleared Suspect Product Notification (if FDA was previously notified): |
- | Within 24 HOURS |
- | * Trading Partner Notification: Within 24 HOURS |
- | * Record Retention for Form 3911 & Logs: 6 YEARS |
- +-----------------------------------------------------------------------------+
- Disposition and Recordkeeping of Illegitimate Products
Illegitimate products represent a public health hazard and must never re-enter commercial distribution .
Safe Disposition: The pharmacy must coordinate with the FDA or a licensed reverse distributor to safely dispose of/destroy the illegitimate product.
Sample Retention: The pharmacy must retain representative samples of the illegitimate product if requested by the FDA or law enforcement for evidentiary purposes.
6-Year Record Retention: All documentation relating to suspect product investigations, Form FDA 3911 filings, trading partner communications, and disposition certificates must be retained for at least 6 years .